Lista de obras - Kenneth C. Anderson - Dominio Público Uruguay

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

artículo científico publicado en 2007

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

artículo científico publicado en 2015

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

artículo científico publicado en 2016

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

scientific article published on 31 October 2019

A SCID-hu in vivo model of human Waldenström macroglobulinemia

artículo científico publicado en 2005

A clinically relevant SCID-hu in vivo model of human multiple myeloma

artículo científico publicado en 2005

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy

artículo científico publicado en 2016

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

artículo científico publicado en 2018

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma

artículo científico publicado en 2004

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

artículo científico publicado en 2009

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

artículo científico publicado en 2019

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

scientific article published on 01 January 2020

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

artículo científico publicado en 2013

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.

artículo científico

A new era of immune therapy in multiple myeloma

artículo científico publicado en 2016

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

artículo científico publicado en 2016

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

artículo científico publicado en 2010

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

scientific article published on 14 February 2020

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

artículo científico publicado en 2016

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

artículo científico publicado en 2005

A novel immunogenic CS1‐specific peptide inducing antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma ⬇️

artículo científico publicado el 26 de abril de 2012

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

artículo científico publicado en 2010

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

artículo científico publicado en 2005

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

artículo científico publicado en 2014

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells ⬇️

artículo científico publicado el 31 de marzo de 2011

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

artículo científico publicado el 18 de agosto de 2011

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2019

A phase 2 study of bortezomib in relapsed, refractory myeloma

artículo científico publicado en 2003

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

artículo científico publicado en 2014

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2011

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

artículo científico publicado en 2010

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

artículo científico publicado en 2006

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

artículo científico publicado en 2017

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

artículo científico publicado en 2008

A strategic framework for novel drug development in multiple myeloma

artículo científico publicado en 2007

AACR Cancer Progress Report 2013.

artículo científico publicado en 2013

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

artículo científico publicado en 2016

Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma

artículo científico publicado en 2002

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

artículo científico publicado en 2010

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

artículo científico publicado en 2012

Advances in biology of multiple myeloma: clinical applications

artículo científico publicado en 2004

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

artículo científico publicado en 2008

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

artículo científico publicado en 2006

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model

artículo científico publicado en 2007

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

artículo científico publicado en 2007

An update of novel therapeutic approaches for multiple myeloma

artículo científico publicado en 2004

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

artículo científico publicado en 2008

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

artículo científico publicado en 2018

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration

artículo científico publicado en 2013

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

artículo científico publicado en 2007

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

artículo científico publicado en 2009

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide ⬇️

artículo científico publicado el 23 de marzo de 2011

Antimyeloma activity of heat shock protein-90 inhibition.

artículo científico publicado en 2005

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

artículo científico publicado en 2009

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

artículo científico publicado en 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

Apoptotic signaling in multiple myeloma: therapeutic implications

artículo científico publicado en 2003

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis ⬇️

artículo científico publicado en 2017

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression

artículo científico publicado en 2009

Autologous bone marrow transplantation therapy for multiple myeloma

Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers

artículo científico publicado en 2014

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

artículo científico publicado en 2005

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

artículo científico publicado en 2016

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells

artículo científico publicado en 2009

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

scientific article published on 01 December 2018

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

scientific article published on 19 August 2019

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

artículo científico publicado en 2020

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

artículo científico publicado en 2011

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

artículo científico publicado en 2006

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

artículo científico publicado en 2013

BM mesenchymal stromal cell–derived exosomes facilitatemultiple myeloma progression

artículo científico publicado en 2013

Best treatment strategies in high-risk multiple myeloma: navigating a gray area

artículo científico publicado en 2014

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

artículo científico publicado en 2006

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

artículo científico publicado en 2021

Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies

artículo científico

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

artículo científico publicado en 2009

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines

artículo científico publicado en 2003

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

artículo científico publicado en 2002

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

artículo científico publicado en 2014

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells

artículo científico publicado en 2017

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells ⬇️

artículo científico publicado el 1 de octubre de 2003

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

artículo científico publicado en 2012

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity

artículo científico publicado en 2019

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

artículo científico publicado en 2004

Body mass index, physical activity, and risk of multiple myeloma

artículo científico publicado en 2007

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

artículo científico publicado en 2015

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

artículo científico publicado en 2017

Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients

artículo científico publicado en 2008

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers ⬇️

artículo científico publicado el 1 de septiembre de 2003

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

artículo científico publicado en 2006

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

artículo científico publicado en 2005

Bortezomib in the front-line treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib in the management of multiple myeloma ⬇️

artículo científico publicado el 8 de septiembre de 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

artículo científico publicado en 2009

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

artículo científico publicado en 2008

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2005

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib: proteasome inhibition as an effective anticancer therapy

artículo científico publicado en 2006

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

artículo científico publicado en 2012

Bruton's tyrosine kinase: oncotarget in myeloma ⬇️

artículo científico publicado el 1 de septiembre de 2012

CCR1 as a target for multiple myeloma ⬇️

artículo científico publicado el 24 de mayo de 2011

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

artículo científico publicado en 2002

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

artículo científico publicado en 2002

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling

scientific article published on 14 November 2002

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders

artículo científico publicado en 2006

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

artículo científico publicado en 2009

Can thalidomide improve outcome in patients with multiple myeloma?

scientific article published on 01 November 2006

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

artículo científico publicado en 2012

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

artículo científico publicado en 2004

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

artículo científico publicado en 2008

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating

artículo científico publicado en 2011

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells

artículo científico publicado en 2003

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

artículo científico publicado en 2010

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

artículo científico publicado en 2009

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

artículo científico publicado en 2005

Clinical translation in multiple myeloma: from bench to bedside

artículo científico

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

artículo científico publicado en 2008

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

artículo científico publicado en 2015

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

artículo científico publicado en 2006

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

artículo científico publicado en 2015

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2009

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2007

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

artículo científico publicado en 2004

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

artículo científico publicado en 2005

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

artículo científico publicado en 2006

Comparison of twin and autologous transplants for multiple myeloma

artículo científico publicado en 2008

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

artículo científico publicado en 2012

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens ⬇️

artículo científico publicado el 16 de octubre de 2003

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

artículo científico publicado en 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

artículo científico publicado en 2011

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

artículo científico publicado en 2020

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

artículo científico publicado en 2020

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

scientific article published on 01 May 2019

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia

artículo científico publicado en 2019

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.

artículo científico publicado en 2004

Current therapeutic uses of lenalidomide in multiple myeloma

artículo científico publicado en 2006

Current treatment landscape for relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Cytokines and signal transduction

artículo científico publicado en 2005

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

artículo científico publicado en 2002

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

artículo científico publicado en 2004

Daratumumab granted breakthrough drug status

artículo científico publicado en 2014

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

artículo científico publicado en 2010

Deciphering the chronology of copy number alterations in Multiple Myeloma

artículo científico publicado en 2019

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets

artículo científico publicado en 2013

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

artículo científico publicado en 2014

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

artículo científico publicado en 2019

Development of effective new treatments for multiple myeloma

artículo científico publicado en 2005

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

artículo científico publicado en 2015

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

scientific article published on 13 February 2020

Differential and limited expression of mutant alleles in multiple myeloma

artículo científico publicado en 2014

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

artículo científico publicado en 2016

Disentangling the Myeloma Web ⬇️

artículo científico publicado el 11 de octubre de 2011

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

artículo científico publicado en 2007

Drug insight: thalidomide as a treatment for multiple myeloma

artículo científico publicado en 2005

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

artículo científico publicado en 2016

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

artículo científico publicado en 2018

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

artículo científico publicado en 2010

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma

artículo científico publicado en 2012

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

artículo científico publicado en 2008

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma

artículo científico publicado en 2021

Dysfunctional T regulatory cells in multiple myeloma

artículo científico publicado en 2005

ESAs not the culprit: more studies required

artículo científico publicado en 2008

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

artículo científico publicado en 2014

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

artículo científico publicado en 2015

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells ⬇️

artículo científico publicado el 1 de octubre de 2003

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

artículo científico publicado en 2010

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

artículo científico publicado en 2015

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

artículo científico publicado en 2018

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Emerging drugs in multiple myeloma

artículo científico publicado en 2007

Emerging therapies for multiple myeloma

artículo científico publicado en 2009

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2010

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

artículo científico publicado en 2009

Emerging trends in the clinical use of bortezomib in multiple myeloma

artículo científico publicado en 2005

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

artículo científico publicado el 13 de diciembre de 2012

Epigenetic modulation in hematologic malignancies: challenges and progress

artículo científico publicado en 2009

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

article

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells

artículo científico publicado en 2002

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

artículo científico publicado en 2007

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

artículo científico publicado en 2015

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes ⬇️

artículo científico publicado el 24 de abril de 2003

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion ⬇️

artículo científico publicado el 15 de mayo de 2003

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations

artículo científico publicado en 2003

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

artículo científico publicado en 2006

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

artículo científico publicado en 2005

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

artículo científico publicado en 2006

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

artículo científico publicado en 2005

Fatty acid synthase is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2008

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function

artículo científico publicado en 2004

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications

artículo científico publicado en 2003

Focus on multiple myeloma

artículo científico publicado en 2004

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

scientific article published on 05 June 2006

From the bench to the bedside: emerging new treatments in multiple myeloma

artículo científico publicado en 2007

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

artículo científico publicado en 2009

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

artículo científico publicado en 2017

Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival

artículo científico publicado en 2003

Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation

artículo científico publicado en 2005

Future agents and treatment directions in multiple myeloma

artículo científico publicado en 2013

Future cancer research priorities in the USA: a Lancet Oncology Commission

artículo científico publicado en 2017

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

artículo científico publicado en 2011

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo ⬇️

artículo científico publicado el 31 de agosto de 2012

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2003

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

artículo científico publicado en 2006

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

artículo científico publicado en 2008

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

artículo científico publicado en 2018

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

scientific article published on 23 August 2019

Genomic patterns of progression in smoldering multiple myeloma

scientific article published in Nature Communications

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma

artículo científico publicado en 2018

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

artículo científico publicado en 2005

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

artículo científico publicado en 2017

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

artículo científico publicado en 2012

Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells ⬇️

artículo científico publicado el 4 de enero de 2013

Hematology: Thalidomide maintenance in multiple myeloma

artículo científico publicado en 2009

Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation

artículo científico publicado en 1991

Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells

artículo científico publicado en 2014

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

artículo científico publicado en 2014

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

article

High-throughput oncogene mutation profiling in human cancer

article

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

artículo científico publicado en 2018

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

artículo científico publicado en 2016

Histone deacetylase inhibitors in the treatment for multiple myeloma ⬇️

artículo científico publicado el 10 de marzo de 2013

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

artículo científico publicado en 2005

How I treat plasma cell leukemia

artículo científico publicado en 2012

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance

artículo científico publicado en 2003

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics

artículo científico publicado en 2019

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells

scientific article published on 23 January 2014

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma

artículo científico publicado en 2022

Identification and validation of novel therapeutic targets for multiple myeloma

artículo científico publicado en 2005

Identification of genes modulated in multiple myeloma using genetically identical twin samples

artículo científico publicado en 2003

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee

artículo científico publicado en 2014

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.

artículo científico publicado en 2013

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients

artículo científico publicado en 2020

Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone ⬇️

artículo científico publicado el 11 de junio de 2012

Immune Therapies in Multiple Myeloma

artículo científico publicado en 2016

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

artículo científico publicado en 2004

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

artículo científico publicado en 2002

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

artículo científico publicado en 2003

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

scientific article published on 01 April 2020

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

artículo científico publicado en 2010

Immunotherapy strategies in multiple myeloma

artículo científico

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2009

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells ⬇️

artículo científico publicado el 12 de abril de 2013

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

artículo científico publicado en 2004

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

artículo científico publicado en 2011

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

artículo científico publicado en 2009

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

artículo científico publicado en 2006

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

artículo científico publicado en 2013

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

artículo científico publicado en 2008

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

artículo científico publicado en 2015

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

artículo científico publicado en 2007

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

artículo científico publicado en 2019

Individualizing treatment of patients with myeloma in the era of novel agents.

artículo científico publicado en 2008

Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.

artículo científico publicado en 2004

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies

artículo científico publicado en 2007

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

artículo científico publicado el 10 de enero de 2011

Inhibition of the TGF-beta signaling pathway in tumor cells

artículo científico publicado en 2007

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

artículo científico publicado en 2004

Initial genome sequencing and analysis of multiple myeloma

artículo científico publicado en 2011

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

artículo científico publicado en 2018

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

artículo científico publicado en 2003

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma

artículo científico publicado en 2009

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

artículo científico publicado en 2009

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era

artículo científico publicado en 2017

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.

artículo científico publicado en 2013

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity

artículo científico publicado en 2013

Intracellular protein degradation and its therapeutic implications

artículo científico publicado en 2005

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

artículo científico publicado en 2002

Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer

artículo científico publicado el 1 de octubre de 2011

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

artículo científico publicado en 2012

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

scientific article published on 10 May 2018

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2019

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

artículo científico publicado en 2017

JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells

artículo científico publicado en 2003

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

artículo científico publicado en 2010

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

artículo científico publicado en 2007

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

artículo científico publicado en 2009

Kidney disease associated with plasma cell dyscrasias

artículo científico publicado en 2010

Latest advances and current challenges in the treatment of multiple myeloma ⬇️

artículo científico publicado el 21 de febrero de 2012

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

artículo científico publicado en 2015

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

artículo científico publicado en 2017

Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors

artículo científico publicado en 2015

Lenalidomide after stem-cell transplantation for multiple myeloma

artículo científico publicado en 2012

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

artículo científico publicado en 2009

Lenalidomide enhances anti-myeloma cellular immunity

artículo científico publicado en 2012

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

artículo científico publicado en 2012

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

artículo científico publicado en 2017

Lenalidomide in multiple myeloma

artículo científico publicado en 2006

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

artículo científico publicado el 15 de junio de 2010

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

artículo científico publicado en 2011

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2010

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

artículo científico publicado en 2011

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.

artículo científico publicado en 2014

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

scientific article published on 20 April 2020

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

artículo científico publicado el 1 de junio de 2011

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

artículo científico publicado en 2008

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

artículo científico publicado en 2007

MUC1-C drives MYC in multiple myeloma

artículo científico publicado en 2016

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction ⬇️

artículo científico publicado el 15 de enero de 2013

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

scientific article published on 12 March 2014

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 1 de octubre de 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

artículo científico publicado en 2012

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

artículo científico publicado el 7 de julio de 2011

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

artículo científico publicado en 2016

Maximizing the clinical benefit of novel therapies in multiple myeloma

scientific article published on April 2009

Mcl-1 regulation and its role in multiple myeloma

artículo científico publicado en 2004

Meaningful changes in end-of-life care among patients with myeloma

artículo científico publicado en 2018

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma ⬇️

artículo científico publicado el 1 de noviembre de 2011

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

artículo científico publicado en 2007

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

artículo científico publicado en 2017

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

scientific article published on 23 March 2020

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

artículo científico publicado en 2010

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

artículo científico publicado en 2012

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

artículo científico publicado en 2009

MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma

article

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

artículo científico publicado en 2011

Minimal Residual Disease in Multiple Myeloma ⬇️

artículo científico publicado el 3 de junio de 2013

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

artículo científico publicado en 2012

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

artículo científico publicado en 2011

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

artículo científico publicado en 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

artículo científico publicado en 2005

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

artículo científico publicado en 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

artículo científico publicado en 2002

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

scientific article published on 14 November 2017

Monoclonal antibodies in the treatment of multiple myeloma ⬇️

artículo científico publicado el 21 de julio de 2011

Monoclonal gammopathy of undetermined significance: a consensus statement

artículo científico publicado en 2010

Mouse models of human myeloma

artículo científico publicado en 2007

Moving toward individualized cancer therapies

artículo científico publicado en 2008

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Multiple Myeloma

artículo científico publicado en 2011

Multiple Myeloma: New Insights and Therapeutic Approaches

artículo científico publicado el 1 de enero de 2000

Multiple myeloma

artículo científico publicado en 2009

Multiple myeloma

article

Multiple myeloma

artículo científico publicado en 2002

Multiple myeloma

artículo científico publicado en 2011

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

artículo científico publicado en 2007

Multiple myeloma: biology of the disease ⬇️

artículo científico publicado el 1 de noviembre de 2010

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

artículo científico publicado en 2013

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

artículo científico publicado en 2016

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders ⬇️

artículo científico publicado el 2 de julio de 2012

NF-kappa B as a therapeutic target in multiple myeloma

artículo científico publicado en 2002

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

artículo científico publicado en 2003

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

artículo científico publicado en 2007

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors ⬇️

artículo científico publicado el 1 de enero de 2013

New Strategies in the Treatment of Multiple Myeloma ⬇️

artículo científico publicado el 20 de marzo de 2013

New drugs for myeloma

artículo científico publicado en 2007

New proteasome inhibitors in myeloma

artículo científico

New treatments for multiple myeloma.

artículo científico publicado en 2005

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

artículo científico publicado en 2008

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

scientific article published on 01 December 2018

Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia

artículo científico publicado en 2006

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

artículo científico publicado en 2014

Novel biological therapies for the treatment of multiple myeloma

artículo científico publicado en 2005

Novel biologically based therapeutic strategies in myeloma

artículo científico publicado en 2002

Novel biologically based therapies for Waldenstrom's macroglobulinemia

artículo científico publicado en 2003

Novel biologically based therapies for multiple myeloma

artículo científico publicado en 2002

Novel epitope evoking CD138 antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders ⬇️

artículo científico publicado el 9 de septiembre de 2011

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

artículo científico publicado en 2005

Novel targeted agents in the treatment of multiple myeloma

artículo científico

Novel therapeutic approaches for multiple myeloma

artículo científico publicado en 2003

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

artículo científico publicado en 2007

Novel therapeutic strategies for multiple myeloma

artículo científico publicado en 2015

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma

artículo científico publicado en 2006

Novel therapies for multiple myeloma

artículo científico publicado en 2003

Novel therapies in MM: from the aspect of preclinical studies

artículo científico publicado en 2011

Novel therapies in myeloma

artículo científico publicado en 2007

Novel therapies in the treatment of multiple myeloma

artículo científico publicado en 2009

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

artículo científico publicado en 2007

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

artículo científico publicado en 2003

Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy ⬇️

artículo científico publicado el 1 de enero de 2011

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication

artículo científico publicado en 2016

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

artículo científico publicado en 2014

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2010

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

artículo científico publicado en 2010

PRMT5 inhibitors on the (myeloma) road

Pathogenesis of Myeloma ⬇️

artículo científico publicado el 1 de enero de 2011

Pathological crystallization of human immunoglobulins ⬇️

artículo científico publicado el 30 de julio de 2012

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2004

Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

artículo científico publicado en 2012

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial ⬇️

artículo científico publicado el 11 de octubre de 2011

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study ⬇️

artículo científico publicado el 29 de mayo de 2012

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

artículo científico publicado en 2013

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

artículo científico publicado en 2012

Perspectives for combination therapy to overcome drug-resistant multiple myeloma

artículo científico publicado en 2005

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

artículo científico publicado en 2010

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

artículo científico publicado en 2008

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

artículo científico publicado en 2016

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib ⬇️

artículo científico publicado el 14 de diciembre de 2012

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 30 de enero de 2012

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

artículo científico publicado en 2008

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

artículo científico publicado en 2010

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

artículo científico publicado en 2010

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

artículo científico publicado en 2012

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

artículo científico publicado en 2010

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

artículo científico publicado en 2010

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

artículo científico publicado en 2013

Phase transitions in human IgG solutions

artículo científico publicado en 2013

Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell

scientific article published on 01 June 2007

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

artículo científico publicado en 2017

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary

artículo científico publicado en 2017

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

artículo científico publicado en 2005

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

artículo científico publicado en 2014

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

scientific article published on 13 May 2019

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function ⬇️

artículo científico publicado el 13 de enero de 2012

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

artículo científico publicado en 2012

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

scientific article published on 12 October 2018

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells ⬇️

artículo científico publicado el 26 de septiembre de 2011

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

artículo científico publicado en 2009

Preclinical studies of novel targeted therapies

artículo científico publicado en 2007

Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma

artículo científico publicado en 2020

Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium

artículo científico publicado en 2012

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy ⬇️

artículo científico publicado el 27 de octubre de 2011

Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia ⬇️

artículo científico publicado el 1 de abril de 2013

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

artículo científico publicado en 2017

Prognostic significance of copy-number alterations in multiple myeloma

artículo científico publicado en 2009

Promising therapies in multiple myeloma

artículo científico publicado en 2015

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

artículo científico publicado en 2004

Proteasome inhibition as a new therapeutic principle in hematological malignancies

artículo científico publicado en 2006

Proteasome inhibition as a novel therapeutic target in human cancer.

artículo científico publicado en 2005

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

artículo científico publicado en 2005

Proteasome inhibition in hematologic malignancies

artículo científico publicado en 2004

Proteasome inhibition in multiple myeloma: therapeutic implication

artículo científico publicado en 2005

Proteasome inhibition in the treatment of cancer

artículo científico publicado en 2005

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

artículo científico publicado en 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

artículo científico publicado en 2002

Proteasome inhibitor therapy in multiple myeloma

artículo científico publicado en 2005

Proteasome inhibitors as therapeutics

artículo científico publicado en 2005

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

artículo científico publicado en 2003

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia

artículo científico publicado en 2007

Proteomic Analysis of Waldenstrom Macroglobulinemia

article

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias ⬇️

artículo científico publicado el 1 de abril de 2003

Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13

scientific article published on 18 May 2020

Pyk2 promotes tumor progression in multiple myeloma

artículo científico publicado en 2014

Re: When you look matters: the effect of assessment schedule on progression-free survival

artículo científico publicado en 2008

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

artículo científico publicado en 2017

Recent advances in the treatment of Multiple Myeloma

artículo científico publicado en 2006

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

artículo científico publicado en 2003

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Reply to M. Roschewski et al

artículo científico publicado en 2014

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

artículo científico publicado en 2014

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

artículo científico publicado en 2012

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia ⬇️

artículo científico publicado el 3 de enero de 2013

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia

artículo científico publicado en 2008

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

artículo científico publicado en 2014

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

artículo científico publicado en 2009

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients ⬇️

artículo científico publicado el 1 de octubre de 2010

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

artículo científico publicado en 2009

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma

artículo científico publicado en 2017

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

artículo científico publicado en 2005

Risks of cancer among a cohort of 23,935 men and women with osteoporosis

artículo científico publicado en 2008

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update

artículo científico publicado en 2018

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary

artículo científico publicado en 2018

Role of Interleukin 16 in Multiple Myeloma Pathogenesis: * A Potential Novel Therapeutic Target? ⬇️

artículo científico publicado el 28 de junio de 2012

Role of liposomal anthracyclines in the treatment of multiple myeloma

artículo científico publicado en 2004

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice

artículo científico publicado en 2002

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

artículo científico publicado en 2005

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

artículo científico publicado en 2008

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

artículo científico publicado en 2007

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2009

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2005

Salvage second hematopoietic cell transplantation in myeloma

artículo científico publicado en 2013

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition

artículo científico publicado en 2014

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia

artículo científico publicado en 2010

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

artículo científico publicado en 2019

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

artículo científico publicado en 2005

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone ⬇️

artículo científico publicado el 27 de septiembre de 2012

Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma ⬇️

artículo científico publicado el 7 de diciembre de 2010

Setting the standard for newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 22 de marzo de 2011

Significant biological role of sp1 transactivation in multiple myeloma

artículo científico publicado en 2011

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?

artículo científico publicado en 2009

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

artículo científico publicado en 2005

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

artículo científico publicado en 2009

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications

artículo científico publicado en 2006

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia

artículo científico publicado en 2009

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

artículo científico publicado en 2006

Stem cell transplant for first relapse from the multiple myeloma research foundation

artículo científico publicado en 2006

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells

artículo científico publicado en 2003

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide

artículo científico publicado en 2015

Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery

artículo científico publicado en 2002

Synopsis of a roundtable on validating novel therapeutics for multiple myeloma

artículo científico publicado en 2006

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

artículo científico publicado en 2015

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

artículo científico publicado en 2012

TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes

artículo científico publicado en 2004

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity ⬇️

artículo científico publicado el 7 de mayo de 2013

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

artículo científico publicado en 2010

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

artículo científico publicado en 2011

Tanespimycin as antitumor therapy.

artículo científico publicado en 2011

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

artículo científico publicado en 2008

Targeting B-cell maturation antigen in multiple myeloma

artículo científico

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

artículo científico publicado en 2017

Targeting CD38 alleviates tumor-induced immunosuppression

artículo científico publicado en 2017

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

artículo científico publicado en 2007

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

scientific article published on 01 October 2007

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma

artículo científico publicado en 2017

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation

artículo científico publicado en 2013

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

artículo científico publicado en 2012

Targeting NF-kappaB in Waldenstrom macroglobulinemia

artículo científico publicado en 2008

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

artículo científico publicado en 2006

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling

artículo científico publicado en 2008

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma

artículo científico publicado en 2009

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling

scientific article published on 29 May 2019

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

artículo científico publicado en 2013

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

artículo científico publicado en 2006

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma

scientific article published on 19 March 2020

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

artículo científico publicado en 2002

Targeting proteasome inhibition in hematologic malignancies

artículo científico publicado en 2003

Targeting proteasomes as therapy in multiple myeloma

artículo científico publicado en 2008

Targeting signalling pathways for the treatment of multiple myeloma

artículo científico publicado en 2005

Targeting the UPS as therapy in multiple myeloma

artículo científico publicado en 2008

Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

artículo científico publicado en 2007

Targeting the bone marrow microenvironment in multiple myeloma.

artículo científico publicado en 2015

Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma

artículo científico publicado en 2015

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

artículo científico publicado en 2007

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

artículo científico publicado en 2007

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma

scientific article published on 28 August 2019

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma

artículo científico

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma

artículo científico publicado en 2003

Telomerase inhibitors as anticancer therapy

artículo científico publicado en 2002

Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors

artículo científico publicado en 2002

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

artículo científico publicado en 2008

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

artículo científico publicado en 2005

Thalidomide and immunomodulatory drugs as cancer therapy

artículo científico publicado en 2002

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

artículo científico publicado en 2008

Thalidomide and rituximab in Waldenstrom macroglobulinemia

artículo científico publicado en 2008

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

artículo científico publicado en 2004

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity

scientific article published on 01 July 2008

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 1 de febrero de 2011

Thalidomide: emerging role in cancer medicine

artículo científico publicado en 2002

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

artículo científico publicado en 2007

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

artículo científico publicado en 2015

The International Myeloma Society comes of age.

artículo científico publicado en 2012

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival

artículo científico publicado en 2016

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

artículo científico publicado el 22 de noviembre de 2011

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

artículo científico publicado en 2017

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

artículo científico publicado en 2017

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

artículo científico publicado en 2016

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

artículo científico publicado en 2002

The biological significance of histone modifiers in multiple myeloma: clinical applications

scholarly article by Hiroto Ohguchi et al published 22 August 2018 in Blood Cancer Journal

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

artículo científico publicado en 2018

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The challenge of cross-trial comparisons using limited data

artículo científico publicado en 2014

The current landscape of multiple myeloma treatment

artículo científico publicado en 2008

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

artículo científico publicado en 2007

The emerging role of novel therapies for the treatment of relapsed myeloma

artículo científico publicado en 2007

The evolution and impact of therapy in multiple myeloma

artículo científico publicado en 2010

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease

scientific article published on 01 August 2018

The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation

artículo científico publicado en 2002

The heavy chain diseases: clinical and pathologic features

artículo científico publicado en 2014

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma

artículo científico publicado en 2015

The impact of response kinetics for multiple myeloma in the era of novel agents

scientific article published on 01 October 2019

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

artículo científico publicado en 2013

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

artículo científico

The malignant clone and the bone-marrow environment

artículo científico publicado en 2007

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2009

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

artículo científico publicado en 2018

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

artículo científico publicado en 2004

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

artículo científico publicado el 7 de marzo de 2012

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The proteasome and proteasome inhibitors in multiple myeloma

artículo científico publicado en 2017

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

artículo científico publicado en 2002

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

artículo científico publicado en 2009

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

artículo científico publicado en 2008

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review

artículo científico publicado en 2003

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

artículo científico publicado en 2007

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

artículo científico publicado en 2006

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

artículo científico publicado el 19 de septiembre de 2011

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

artículo científico publicado en 2006

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome

artículo científico publicado en 2009

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

artículo científico publicado en 2007

The treatment of multiple myeloma patients not eligible for asct ⬇️

artículo científico publicado el 3 de mayo de 2010

The treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2007

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2002

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

scientific article published on 26 November 2019

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

artículo científico publicado en 2016

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma

artículo científico publicado en 2006

Timing the initiation of multiple myeloma

scientific article published on 21 April 2020

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

artículo científico publicado en 2003

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

artículo científico publicado en 2016

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

artículo científico publicado en 2004

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane

scientific article published on 01 March 2002

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist

artículo científico publicado en 2018

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.

artículo científico publicado en 2005

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

artículo científico publicado en 2014

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

artículo científico publicado en 2003

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma

artículo científico publicado en 2013

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

artículo científico publicado en 2001

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

artículo científico publicado en 2010

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans ⬇️

artículo científico publicado el 15 de enero de 2013

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

artículo científico publicado en 2007

Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma

artículo científico publicado en 2007

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2008

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

artículo científico publicado en 2016

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

artículo científico publicado en 2004

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

scientific article published on 02 November 2020

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients ⬇️

artículo científico publicado el 17 de mayo de 2013

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma ⬇️

artículo científico publicado el 28 de octubre de 2010

Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation ⬇️

artículo científico publicado el 20 de diciembre de 2001

Velcade and vitamin C: too much of a good thing?

artículo científico publicado en 2006

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

artículo científico publicado en 2003

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

artículo científico publicado en 2013

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

artículo científico publicado en 2011

YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma

artículo científico publicado en 2020

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells

artículo científico publicado en 2002

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia

artículo científico publicado en 2009

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

artículo científico publicado en 2004

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

artículo científico publicado en 2008

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

artículo científico publicado en 2017

“Sowing dragon's teeth?” Myeloma and AML ⬇️

artículo científico publicado el 13 de octubre de 2011

Lista de obras de Kenneth C. Anderson

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

A SCID-hu in vivo model of human Waldenström macroglobulinemia

A clinically relevant SCID-hu in vivo model of human multiple myeloma

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.

A new era of immune therapy in multiple myeloma

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

A novel immunogenic CS1‐specific peptide inducing antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma ⬇️

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells ⬇️

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

A phase 2 study of bortezomib in relapsed, refractory myeloma

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

A strategic framework for novel drug development in multiple myeloma

AACR Cancer Progress Report 2013.

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening

Advances in biology of multiple myeloma: clinical applications

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

An update of novel therapeutic approaches for multiple myeloma

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide ⬇️

Antimyeloma activity of heat shock protein-90 inhibition.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

Apoptotic signaling in multiple myeloma: therapeutic implications

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis ⬇️

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression

Autologous bone marrow transplantation therapy for multiple myeloma

Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

BM mesenchymal stromal cell–derived exosomes facilitatemultiple myeloma progression

Best treatment strategies in high-risk multiple myeloma: navigating a gray area

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies